Table 2.

Incidence of the least common any grade irAEs in pivotal first-line metastatic studies

Study name	Immunotherapy and dose	Additional agents	Tumour	irAEs	Incidence (%)
Checkmate 067 [10]	Ipilimumab 3 mg/kg Nivolumab 1 mg/kg	Nil	Melanoma	Hypersensitivity Renal Pneumonitis	4 7 8
KEYNOTE 024 [11]	Pembrolizumab 200 mg	Nil	NSCLC	T1DM Pancreatitis Nephritis	0.6 0.6 0.6
Checkmate 214 [12]	Ipilimumab 1 mg/kg Nivolumab 3 mg/kg	Nil	RCC	Thrombocytopenia PPE HTN	< 1 < 1 < 1
KEYNOTE 048 [13]	Pembrolizumab 200 mg	Monotherapy, platinum and 5-FU based chemotherapy arms	Head and neck SqCC	Uveitis Hypophysitis Encephalitis	< 1 < 1 < 1
IMbrave150 [14]	Atezolizumab 1200 mg	Bevacizumab 15 mg/kg	HCC	PPE Alopecia Asthenia	0.9 1.1 6.7
TOPAZ-1 [15]	Durvalumab 1500 mg	Cisplatin Gemcitabine	Cholangiocarcinoma	Thyroiditis Hypophysitis Pancreatitis	0.3 0.3 0.3
Checkmate 649 [16]	Nivolumab 240 mg or 360 mg	FOLFOX	Gastric adenocarcinoma	Renal Pulmonary Endocrine	3 5 14
JAVELIN Bladder 100 [17]	Avelumab 10 mg/kg	Cisplatin/carboplatin-gemcitabine	Urothelial carcinoma	Infusion reaction Anaemia Rash	10.2 11.3 11.6
Checkmate 743	Ipilimumab 1 mg/kg Nivolumab 3 mg/kg	Nil	Mesothelioma	Opsoclonus myoclonus Vasculitis AST rise	0.3 0.3 0.3

HCC hepatocellular carcinoma, HTN hypertension, irAE immune-related adverse event, NSCLC non-small cell lung cancer, PPE palmar-plantar erythrodysesthesia, RCC renal cell carcinoma, SqCC squamous cell carcinoma, T1DM type 1 diabetes mellitus